HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TXMD
TherapeuticsMD, Inc.
There isn't enough reported data to score TXMD yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TXMD Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Strong | |
| Strong |
TXMD's cash flow and balance sheet are currently strong, but its profitability is weak. There isn't enough data to rate its revenue.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TXMD PE Valuation
TXMD has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TXMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect TXMD's revenue to grow, with its earnings and profitability holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
TXMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.02 | +$0.03 |
| Q1 2026 | $0.02 | +$0.21 |
| Q4 2025 | -$0.05 | +$0.14 |
| Q3 2025 | $0.01 | +$0.26 |
| Q2 2025 | -$0.05 | +$0.47 |
| Q1 2025 | -$0.19 | +$0.48 |
| Q4 2024 | -$0.19 | +$0.79 |
| Q3 2024 | -$0.25 | -103% |
TXMD has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over TXMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over TXMD on profitability, with a higher operating margin.
TXMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $869K | -8.7% |
| Q1 2026 | $724K | +84% |
| Q4 2023 | $502K | -56% |
| Q2 2023 | $437K | -98% |
| Q1 2023 | $416K | -98% |
| Q4 2022 | $1.2M | -94% |
| Q3 2022 | $20.9M | -18% |
| Q2 2022 | $28.6M | +24% |
TXMD's revenue is growing: $869,000 last quarter, down 8.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -94% | -21 points |
| Q1 2026 | -100% | +122 points |
| Q4 2025 | -174% | N/A |
| Q3 2025 | -110% | N/A |
| Q2 2025 | -73% | N/A |
| Q1 2025 | -222% | N/A |
| Q4 2023 | -321% | -6138 points |
| Q2 2023 | -566% | -500 points |
TXMD's operating margin was −94% last quarter, down 21 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
TXMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $779K | +104% |
| Q1 2026 | $944K | +35% |
| Q4 2025 | $375K | +2106% |
| Q3 2025 | $999K | +$1.1M |
| Q2 2025 | $381K | -74% |
| Q1 2025 | $699K | +$928K |
| Q4 2024 | $17K | +$5M |
| Q3 2024 | -$71K | +$2.4M |
TXMD has burned cash in most quarters: $3M over the past year, about three times what it generated the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TXMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TXMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +74K shares |
| 1 year | +0.8% | +91K shares |
| 3 years | +24% | +2.3M shares |
| 5 years | +114% | +6.2M shares |
| Available history | +141% | +6.8M shares |
TXMD has 12M diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2023 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TXMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2023 | -0.0x | Net Cash |
| Q2 2023 | -0.3x | Net Cash |
| Q1 2023 | -0.7x | Net Cash |
| Q4 2022 | -16.0x | Net Cash |
TXMD has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TXMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.0 | Neutral |
| Stochastic | 18.2 | Oversold |
TXMD's weekly RSI is 41 (neutral) and its Stochastic is 18 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TXMD PE vs Healthcare Sector
| Metric | TXMD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TXMD has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TXMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.90 | 4.2% below |
| 20 week MA | $2.02 | 9.9% below |
| 50 week MA | $2.06 | 12% below |
| 100 week MA | $1.62 | 12% above |
| 200 week MA | $2.20 | 17% below |
TXMD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
TXMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $120.5 | $59.5 | -51% |
| 2021 | $59.5 | $20.5 | -66% |
| 2022 | $20.5 | $5.62 | -73% |
| 2023 | $5.62 | $2.25 | -60% |
| 2024 | $2.25 | $1.09 | -52% |
| 2025 | $1.09 | $1.74 | +60% |
| 2026 YTD | $1.74 | $1.82 | +4.6% |
TXMD has the edge over HIMS on returns for 2026, with the stronger performance.